The purpose of this file is the centralized contracting of the supply of the drugs HIERRO SACAROSA (DOE), DEXCLORFENIRAMINA (DOE), METADONA (DOE) 10MG / ML CONCENTRATE FOR ORAL SOLUTION, CEFAZOLINE (DOE), ONDANSETRON (DOE) SOLUTION FOR PERFUSION AND NITISINONA (DOE) for all Osakidetza service organizations and privately owned and non-profit health centers, located in the Autonomous Community of Euskadi, within the framework provided in article 30 of Law 8/1997, of 26 June, of the Health Organization of Euskadi, to sign a linkage agreement with Osakidetza / Basque Health Service.
With this contracting file whose conditions are established in this document, it is intended to cover the needs in Osakidetza for the use of the drugs included in the file for therapeutic indications approved by the competent health authority and which are summarized in the report's report.
Active substance: Iron-sucrose [sucrose complex and iron hydroxide (III)]
Amount of active substance: 20 mg / ml
Pharmaceutical Form: 5 ml ampoule
Packaging conditions: Unit dose
Maximum unit price: 1.00 euros / 5 ml ampoule
(Taxes not included)
N
(First year of contract)
Maximum estimated budget: 58,000.00 euros
(First year of contract)
Active substance: DEXCLORFENIRAMINA (DOE)
Amount of active substance: 5 mg / ml
Pharmaceutical Form: 1ml ampoule
Packaging conditions: unit dose
Maximum unit price: 0.52 euros / 1ml ampoule
(Taxes not included)
N
(First year of contract)
Maximum estimated budget: € 31,200.00
(First year of contract)
Active substance: METADONA (DOE)
Amount of active substance: 10mg / ml
Pharmaceutical Form: concentrate for oral solution
Packaging conditions: unit dose
Maximum final price: 34.00 euros / 1,000ml bottle
(Taxes not included)
N
(Three years of contract)
Maximum estimated budget: 17,680.00 euros
(Three years of contract)
LOT FOUR - CEFAZOLINA (DOE)
Active ingredient: CEFAZOLINE (DOE)
Amount of active substance: 1 g and 2 g
Pharmaceutical form: vial
Packaging conditions: unit dose
Maximum unit price: 0.57 euros / 1 g vial
(Taxes not included) 1.14 euros / 2g vial
N
(First year of contract) 38,000 vials of 2 g intravenous
Maximum estimated budget: 88,920.00 euros
(First year of contract)
LOT FIVE - ONDANSETRON (DOE) PERFUSION SOLUTION
Active substance: ONDANSETRON (DOE)
Amount of active substance: 0.08 mg / ml and 0.16mg / ml
Pharmaceutical form: solution for infusion
Packaging conditions: unit dose
Maximum unit price: 7.50 euros / container of 10 bottles of 100ml of 0.08mg / ml
(Taxes not included) 15.00 euros / pack of 10 bottles of 50ml of 0.16 mg / ml
N
(First year of contract) 1,000 containers of 10 bottles of 50ml of 0.16 mg / ml
Maximum estimated budget: 15,750.00 euros
(First year of contract)
LOT SIX- NITISINONA (DOE) 5 AND 10MG
Active substance: NITISINONE (DOE)
Amount of active substance: 5 mg and 10 mg
Pharmaceutical form: capsule
Packaging conditions: unit dose preferably
Maximum price: 1,371.67 euros / pack of 60 capsules of 5 mg
(Taxes not included) 2,507.44 euros / pack of 60 capsules of 10 mg
N
(First year of contract) 140 packages of 60 capsules of 10 mg
Maximum estimated budget: 378,475.00 euros
(First year of contract)
LOT SEVEN - NITISINONA (DOE) 2MG
Active substance: NITISINONE (DOE)
Amount of active substance: 2 mg
Pharmaceutical form: capsule
Packaging conditions: unit dose preferably
Maximum price: 685.84 euros / pack of 60 capsules of 2 mg
(Taxes not included)
N
(First year of contract)
Maximum estimated budget: 20,575.20 euros
(First year of contract)
LOT EIGHT - NITISINONA (DOE) 20MG AND 4MG / ML
Active substance: NITISINONE (DOE)
Amount of active substance: 20mg and 4mg / ml
Pharmaceutical form: capsule and oral suspension
Packaging conditions: unit dose preferably
Maximum price: 4,365.90 euros / pack of 60 capsules of 20 mg
(Taxes not included) 2,239.06 euros / bottle of 90ml in oral suspension
N
(First year of contract) 50 bottles of 90ml in oral suspension
Maximum estimated budget: 86,589.00 euros
(First year of contract)